Currently, there are only three FDA-approved FLT3 inhibitors, sorafenib, midostaurin, and gilteritinib, for use in the U.S. Of these, only two are approved for AML indication: midostaurin, along with chemotherapy, and gilteritinib [98]. This evidence concerns the gene FLT3 and acute myeloid leukemia.